col-91 Antibody

Introduction to CD91 Antibody

CD91, also known as Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1), is a transmembrane receptor critical for endocytosis, cell signaling, and immune regulation. Monoclonal antibodies targeting CD91, such as clone A2MR-a2, are widely used in research to study its structural and functional roles . CD91 antibodies enable precise detection and analysis of this receptor in diverse biological systems, including antigen presentation, lipid metabolism, and cellular homeostasis .

Molecular Structure and Characteristics

CD91 is a type 1 transmembrane protein composed of two subunits:

• Alpha chain: Binds ligands such as heat shock proteins, proteases, and lipoproteins.

• Beta chain: Contains tyrosine phosphorylation motifs for intracellular signaling .

Key pathways:

• Interaction with LRPAP1 (α2-macroglobulin receptor-associated protein) .

• Modulation of plasminogen activator inhibitor complexes .

Research Applications

• Flow cytometry: CD91 antibodies (e.g., A2MR-a2) are validated for detecting CD91 on human peripheral blood cells .

• Immunohistochemistry: Used to localize CD91 in tissues such as brain, lung, and adipose tissue .

• Functional studies: Investigate roles in neurodegenerative diseases, cancer metastasis, and immune responses .

Therapeutic Potential

While no CD91-targeted therapies are currently approved, its involvement in disease pathways highlights potential:

• Cancer: CD91 overexpression in tumors correlates with metastasis and drug resistance .

• Neurodegeneration: Regulates amyloid-β clearance in Alzheimer’s disease models .

• Autoimmunity: Modulates inflammatory signaling in macrophages .

Preclinical Data

• Antigen presentation: CD91 antibodies block cross-presentation of heat shock protein-bound antigens, impairing dendritic cell activation .

• Knockout models: Mice lacking CD91 exhibit defective lipid metabolism and increased atherosclerosis .

Challenges and Future Directions

• Immunogenicity: Murine-derived CD91 antibodies may trigger immune responses in humans, necessitating humanized variants .

• Functional complexity: CD91’s dual role in pro- and anti-inflammatory pathways complicates therapeutic targeting .

Emerging technologies like phage display and single-cell sequencing could advance CD91 antibody engineering for clinical use .